No Association of Early-Onset Breast or Ovarian Cancer with Early-Onset Cancer in Relatives in BRCA1 or BRCA2 Mutation Families

Archive ouverte

Imbert-Bouteille, Marion | Corsini, Carole | Picot, Marie-Christine | Mizrahy, Lucas | Akouete, Sandrine | Huguet, Helena | Thomas, Frédéric | Geneviève, David | Taourel, Patrice | Ychou, Marc | Galibert, Virginie | Rideau, Chloé | Baudry, Karen | Kogut-Kubiak, Tatiana | Coupier, Isabelle | Hobeika, Rémy | Macary, Yvette | Toledano, Alain | Solassol, Jérôme | Maalouf, Antoine | Daurès, Jean-Pierre | Pujol, Pascal

Edité par CCSD ; MDPI -

International audience. According to clinical guidelines, the occurrence of very early-onset breast cancer (VEO-BC) (diagnosed ≤ age 30 years) or VEO ovarian cancer (VEO-OC) (diagnosed ≤ age 40 years) in families with BRCA1 or BRCA2 mutation (BRCAm) prompts advancing the age of risk-reducing strategies in relatives. This study aimed to assess the relation between the occurrence of VEO-BC or VEO-OC in families with BRCAm and age at BC or OC diagnosis in relatives. We conducted a retrospective multicenter study of 448 consecutive families with BRCAm from 2003 to 2018. Mean age and 5-year–span distribution of age at BC or OC in relatives were compared in families with or without VEO-BC or VEO-OC. Conditional probability calculation and Cochran–Mantel–Haenszel chi-square tests were used to investigate early-onset cancer occurrence in relatives of VEO-BC and VEO-OC cases. Overall, 15% (19/245) of families with BRCA1m and 9% (19/203) with BRCA2m featured at least one case of VEO-BC; 8% (37/245) and 2% (2/203) featured at least one case of VEO-OC, respectively. The cumulative prevalence of VEO-BC was 5.1% (95% CI 3.6–6.6) and 2.5% (95% CI 1.4–3.6) for families with BRCA1m and BRCA2m, respectively. The distribution of age and mean age at BC diagnosis in relatives did not differ by occurrence of VEO-BC for families with BRCA1m or BRCA2m. Conditional probability calculations did not show an increase of early-onset BC in VEO-BC families with BRCA1m or BRCA2m. Conversely, the probability of VEO-BC was not increased in families with early-onset BC. VEO-BC or VEO-OC occurrence may not be related to young age at BC or OC onset in relatives in families with BRCAm. This finding—together with a relatively high VEO-BC risk for women with BRCAm—advocates for MRI breast screening from age 25 regardless of family history.

Suggestions

Du même auteur

Clinical practice guidelines for BRCA1 and BRCA2 genetic testing

Archive ouverte | Pujol, Pascal | CCSD

International audience. BRCA1 and BRCA2 gene pathogenic variants account for most hereditary breast cancer and are increasingly used to determine eligibility for PARP inhibitor (PARPi) therapy of BRCA-related cancer...

Guidelines for reporting secondary findings of genome sequencing in cancer genes: the SFMPP recommendations

Archive ouverte | Pujol, Pascal | CCSD

IF 3.636 (2017). International audience. In oncology, the expanding use of multi-gene panels to explore familial cancer predisposition and tumor genome analysis has led to increased secondary findings discoveries (S...

Early onset breast cancer: differences in risk factors, tumor phenotype, and genotype between North African and South European women

Archive ouverte | Corsini, Carole | CCSD

International audience. PURPOSE: This report compares the risk factors, the tumor phenotypes, and the BRCA1/BRCA2 genotype of early onset breast cancer (EOBC) patients between Southern Europe and North Africa. METHO...

Chargement des enrichissements...